Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations: Part III: The chronic leukemias and myelofibrosis

Aging Clinical and Experimental Research

Volumn 9, Issue 6, 1997, Pages 383-390

  Quaglino, D ^a   Di Leonardo, G ^a   Furia, N ^a   Pasqualoni, E ^a   Campitelli, A ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Chronic leukemias; Elderly; Myelofibrosis; Myeloid metaplasia.

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; ALPHA INTERFERON; BUSULFAN; CLADRIBINE; CORTICOSTEROID; DOXORUBICIN; FLUDARABINE; HYDROXYUREA; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PENTOSTATIN; PREDNISOLONE; TIOGUANINE;

AGING; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; ELDERLY CARE; MYELOFIBROSIS; PROGNOSIS; REVIEW; SPLENECTOMY; STEM CELL TRANSPLANTATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT PLANNING;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID, CHRONIC; MYELOFIBROSIS;

EID: 0031417202     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Champlin R.E., Goldman J.M., Gale R.P.: Bone marrow transplantation in chronic myelogenous leukaemia. Semin. Haematol. 25: 74-80, 1988.
2. Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champling R.E., Gluckman E., Hoffman R.G., Jacobsen S.J., Marmont A.M., McGlave P.B., Messner H.A., Rimm A.A., Rozman C., Speck B., Tura S., Weiner R.S., Bortin M.M.: Bone marrow transplantation for chronic myelogenous leukaemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann. Intern. Med. 108: 806-814, 1988.
3. Galton D.A.G.: Chemotherapy of chronic myelocytic leukaemia. Semin. Hematol. 6 323-343, 1969.
4. Kennedy B.J., Yarbro J.W.: Hydroxyurea in chronic myeloid leukaemia. JAMA 195: 1038-1044, 1966.
5. Schwartz J.H., Canellos G.P.: Hydroxyurea in the management of the haematologic complications of chronic granulocytic leukaemia. Blood 46: 11-16, 1975.
6. Talpaz M., Mc Credie K., Kantarjian H.M., Trujillo J., Keating M., Gutterman J.: Chronic myelogenous leukaemia, haematological remission with alpha-interferon. Br. J. Haematol 64: 87-95, 1986.
7. Talpaz M., Kantarjian H.M , McCredie K., Keating M.J., Trujillo J., Gutterman J : Clinical investigation of human alpha interferon in chronic myelogenous leukaemia. Blood 5: 1280-1288, 1987.
8. Han T., Ozer H., Gavigan M., Gajera R., Minowada J., Bloom M.L , Sadamori N., Sandberg A.R., Gomez G A , Henderson E.S : Benign monoclonal B cell Lymphocytosis-a benign variant of CLL: clinical, immunologic, phenotypic and cytogenetic studies in 20 patients. Blood 64: 244-252, 1984.
9. Rai K R., Sawmsky A., Cronkite E P., Chanana A.D , Levy R.N., Pastemack B.S.: Clinical staging of chronic lymphocytic leukaemia. Blood 46: 219-234, 1975.
10. Binet J.L., Auquier A., Dighiero G., Chastang C., Piquet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchemia G., Jacquillat C., Boivin P., Lesty C., Duault M.T., Monconduit M., Belabbes S., Gremy F.: A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis. Cancer 48; 198-206, 1981.
11. Report from the International Workshop on CLL: Chronic Lymphocytic Leukaemia: proposals for a revised prognostic staging system. Br. J. Haematol. 48: 365-367, 1981.
12. Baccarani M., Cavo M., Gobbi M., Lauria F., Tura S.: Staging of chronic lymphocytic leukaemia. Blood 59. 1191-1196, 1982.
13. Geisler C., Ralekiaer E., Morkhansen M., Hou-Jensen K., Olesen Larsen S.: The bone marrow histological pattern has independent prognostic value in early stage chronic lymphocytic leukaemia. Br. J. Haematol. 62: 47-54, 1986.
14. Melo J.V., Catovsky D , Gregory W.M., Galton D.A.G : The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br. J. Haematol. 65: 23-29, 1987
15. Montserrat E., Sanchez Bixono J., Vinoias N., Rozman C : Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br. J. Haematol. 62: 567-575, 1986.
16. Molica S., Albert A.: Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukaemia. Cancer 60: 2712-2716, 1987.
17. Pittmans S , Catousky D.: Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia Br. J. Haematol 58: 649-660, 1984.
18. Juliusson G.: Immunologic and cytogenetic studies improve prognostic prediction in chronic B-lymphocytic leukaemia. Cancer 58. 688-693, 1986.
19. Rozman C , Montserrat E., Vinolas N.: Serum immunoglobulins in B-chronic lymphocytic leukaemia: natural history and prognostic significance. Cancer 61. 279-283, 1988.
20. Lee J.S., Dixon D.O., Kantarjian H.M., Keating M.J.,Talpaz M.: Prognosis of chronic lymphocytic leukaemia: a multivariate regression analysis of 325 untreated patients. Blood 69. 929-936, 1987.
21. Catovsky D., Fooks J., Richards S S , for the MRC Working Party on leukaemia in adults: Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC 1 Trial. Br. J. Haematol. 72: 141-149, 1989.
22. Rozman C., Montserrat E., Vinolas N., Urbano-Ispizua A., Ribera J.M., Gallart T., Compernolle C.: Recombinant α2-interferon in the treatment of B chronic lymphocytic leukaemia in early stages. Blood 71: 1295-1298, 1987.
23. Ziegler-Heitbrock H W.L., Schlag R , Rieger D., Thiel E.: Favorable response of early stage B CLL patients to treatment with IFN-α2. Blood 73: 1426-1430, 1989.
24. Keating M.J., O'Brien S., Kantarjian H.M., Piunkett W., Estey E., Koller C., Beran M., Freireich E J.: Long-term follow-up of patients with chronic lymphocytic leukaemia treated with fludarabine as a single agent. Blood 81: 2878-2884, 1993.
25. French Cooperative Group on CLL. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347: 1432-1438, 1996.
26. Rosenthal D.S., Moloney W.C., Myeloid metaplasia: a study of 98 cases. Postgrad. Med. 45: 136-143, 1969.
27. Quaglino D., Hayhoe F.G.J.: Haematological Oncology. Clinical Practice Churchill Livingstone, Edinburgh, London, p. 222, 1992.
28. Roberts B.E., Miles D.W., Wood C G : Polycythaemia and myelosclerosis: a bone marrow study. Br. J. Haematol. 16: 75-85, 1969.
29. Adamson J.W., Fialkow P.J.: The pathogenesis of myeloproliferative syndromes. Br. J. Haematol. 38: 299-303, 1978.
30. Groopman J.E.: The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann. Intern. Med. 92: 857-858, 1980.
31. McCarthy D.M : Fibrosis of the bone marrow content and causes. Br. J. Haematol. 59: 1-7, 1985.
32. Sporn M.B , Roberts A.B , Wakefield L.M., Assoian R.K.: Transforming growth factor-b, biological function and chemical structure. Science 233: 532-534, 1986.
33. Kimura A., Katoh O., Kuramoto A.: Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens. Br. J. Haematol. 69: 153-156, 1988.
34. Cappio F.C., Vigliani R., Novarino A., Camussi G., Campana D., Gavosto F . Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br. J. Haematol. 49: 17-21, 1981.
35. Barosi G., Baraldi A., Cazzola M., Spriano P., Magrini V.: Red cell aplasia in myelofibrosis with myeloid metaplasia A distinct functional and clinical entity. Cancer 52. 1290-1296, 1983.
36. Polino G., Barosi G , Berzuini A.: Fatty bone marrow with severe myeloid hypoplasia in idiopathic myelofibrosis. Haematologica 71: 117-121, 1986.
37. Wolf B.C., Neiman R.S : Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 65: 803-809, 1985.
38. Barosi G., Liberato L.N., Guarnone R.: Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 83: 365-369, 1993.
39. Barosi G., Cazzola M., Frassoni F , Orlandi E., Stefanelli M.: Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics. Br J. Haematol. 48: 263-272, 1981.
40. Thiele J., Zankovich R., Steinberg T., Fischer R., Diehl V., Agnogenic myeloid metaplasia (AMM): correlation of bone marrow lesions with laboratory data. A longitudinal clinical pathological study on 114 patients. Haematol. Oncol. 7: 327-343, 1989a
41. Thiele J., Zankovich R., Steinberg T., Kremer B., Fischer R , Diehl V.: Primary (essential) thrombocythaemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis: a critical evaluation of clinical and histomorphological data. Acta Haematol. 81: 192-202, 1989b.
42. Bouroncle B.A., Doan C.A.: Myelofibrosis, clinical haematological and pathologic study of 110 patients. Am. J. Med. Sci. 243: 697-715, 1962.
43. Lofvenberg E., Wahlin A., Roos G., Ost A.: Reversal of myelofibrosis by hydroxyurea Eur. J. Haematol. 44: 33-38, 1990.
44. Gardner F H., Pringle J.C. Jr: Androgens and erythropoiesis. II. Treatment of myeloid metaplasia. N. Engl. J. Med. 264: 106-110, 1960.
45. Besa E.C., Nowell P.C., Geller N.I., Gardner F.: Analysis of androgen response of 23 patients with agnogenic myeloid metaplasia. Cancer 49: 308-313, 1982.
46. Chabannon C , Pegourie B., Sotto J.J., Hallard D.: Clinical and haematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia. Nouv. Rev. Fr. Hematol. 32: 165-166, 1990.
47. Wagner H. Jr, Mckenough P.G., Desforges J., Madoc-Jones H.: Splenic irradiation in the treatment of patients with chronic myelogenous leukaemia or myelofibrosis with myeloid metaplasia. Cancer 58: 1204-1207, 1986.
48. Benbassat J., Gilon D., Penchas S.: The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am. J Hematol. 33: 128-135, 1990.
49. McCarthy D., Clark J., Giles F.: The treatment of myelofibrosis with alpha-interferon. Br. J. Haematol. 78: 590-591, 1991.
50. List A.F., Doll D.C.: Alpha-interferon in the treatment of idiopathic myelofibrosis. Br. J. Haematol 80. 566-567, 1992.
51. 3 in the treatment of idiopathic myelofibrosis. Br. J. Haematol. 64: 624-625, 1986.
52. 3 in the treatment of idiopathic myelofibrosis (Letter). Br. J. Haematol. 65: 381, 1987.